iCAD to Highlight Xoft System to Treat Skin, Breast and Gynecological Cancers at ASTRO

  iCAD to Highlight Xoft System to Treat Skin, Breast and Gynecological
  Cancers at ASTRO

2013 ASTRO Annual Meeting

Business Wire

NASHUA, N.H. & ATLANTA -- September 19, 2013

ASTRO Booth Number 2449--iCAD, Inc. (Nasdaq: ICAD), an industry-leading
provider of advanced image analysis, workflow solutions and radiation therapy
for the early identification and treatment of cancer, today announced that its
Xoft subsidiary will be showcasing its Xoft^® Axxent^® Electronic
Brachytherapy System^® at the American Society for Radiation Oncology’s
(ASTRO) 55^th Annual Meeting being held from September 22-25, 2013 in Atlanta
at booth #2449. The Xoft System can be used to treat non-melanoma skin cancer
(NMSC), early-stage breast cancer with Intraoperative Radiation Therapy (IORT)
and Accelerated Partial Breast Irradiation (APBI), vaginal, endometrial and
cervical cancer.

“This year’s activities at ASTRO demonstrate iCAD’s commitment to delivering
targeted, innovative and cost-effective radiation therapy solutions to
radiation oncologists to help them to more effectively treat a variety of
cancers,” said Ken Ferry, President and CEO of iCAD. “It’s an exciting time
for iCAD with new product introductions, significant progress in our
post-market breast cancer study, and the presentation of longer term clinical
data that supports the increased momentum of our NMSC application.”

The Company’s technology will be featured in the following educational
sessions and at the Company’s booth:

Industry-Expert Theater
                  
Topic:                  “Electronic Brachytherapy Utilizing the Xoft^® System
                        for the Treatment of Non-Melanoma Skin Cancer”
                        
Presentation:           Monday, September 23 from 10:15 to 10:45 a.m.
                        
                        Ajay Bhatnagar, MD, MBA, Cancer Treatment Services
Presenter:              Arizona, Affiliate of 21^st Century Oncology, Adjunct
                        Assistant Professor of Radiation Oncology, University
                        of Pittsburgh School of Medicine and DermEbx
                        
Location:               Rear of 100 Aisle, Exhibit Hall B1
                        
New Data on the Use of the Xoft System for Non-Melanoma Skin Cancer (NMSC)
                        
                        “Electronic Brachytherapy for the Treatment of
                        Non-Melanoma Skin Cancer: Results at Three Years,”
Topic:                  which presents new clinical data assessing adverse
                        effects, cosmesis and recurrence rates related to high
                        dose rate (HDR) electronic brachytherapy for the
                        treatment of NMSC with the Xoft System.
                        
Presentation:           Tuesday, September 24 at 2:10 p.m.
                        
Presenter:              Dr. Bhatnagar
                        
Location:               Scientific Session S in Room B405
                        
Breast IORT Post-market Study Update
                        
                        “A Safety and Efficacy Study of Intra-Operative
                        Radiation Therapy (IORT) using the Xoft Axxent eBx
                        System at the Time of Breast Conservation Surgery for
Topic:                  Early-Stage Breast Cancer,” providing discussion of
                        the ongoing study, which has 19 participating centers
                        and more than 150 patients treated and which continues
                        to enroll patients and enlist centers.
                        
Presentation:           Throughout Exhibit Hall hours
                        
Location:               iCAD Exhibit Booth 2449
                        

About ASTRO

Radiation oncologists, medical physicists, dosimetrists, radiation therapists,
radiation oncology nurses and nurse practitioners, biologists, physician
assistants and practice administrators comprise ASTRO’s nearly 10,000 members,
making it the largest radiation oncology organization of its kind. These
medical professionals, found at hospitals, cancer treatment centers and
academic research facilities around the globe, make up the radiation therapy
treatment teams that are critical in the fight against cancer. Together, these
teams, treat more than 1 million cancer patients each year.

ASTRO provides members with the continuing medical education, health policy
analysis, patient information resources and advocacy that they need to succeed
in today’s ever-changing health care delivery system.

About Xoft Axxent Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment cleared by the U.S.
Food and Drug Administration and CE marked in the EU for use anywhere in the
body, including for the treatment of early stage breast cancer, endometrial
cancer, cervical cancer and skin cancer. It utilizes a proprietary
miniaturized x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and organs. A
post-market study is underway to assess the safety and efficacy of
Intraoperative Radiation Therapy with the Xoft System. Xoft is a wholly owned
subsidiary of iCAD, Inc. For more information about Xoft visit
www.xoftinc.com.

About iCAD, Inc.

iCAD is a leading provider of advanced image analysis, workflow solutions and
radiation therapies for the early identification and treatment of common
cancers. iCAD offers a comprehensive range of high-performance, upgradeable
CAD solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate cancers and
Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers
radiation treatment for early-stage breast cancer that can be administered in
the form of intraoperative radiation therapy or accelerated partial breast
irradiation. The Xoft System is also cleared for the treatment of non-melanoma
skin cancer, cervical cancer and endometrial cancer. For more information,
call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995:

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the Company’s
ability to identify a replacement for the Axxent FlexiShield Mini, the risks
relating to the Company’s acquisition of Xoft including, the expected benefits
of the acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.

Contact:

For iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
For iCAD investor relations
LHA
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For iCAD media inquiries
Schwartz MSL
Helen Shik, 781-684-0770
iCAD@schwartzmsl.com